Stage and activity guide management. Supplements are for selected risk groups; anti-VEGF treats active neovascular disease, and slowing atrophy growth is not the same as improving vision.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Start with stage and clinical urgency
AMD is an important cause of severe central visual impairment in older Western populations; it does not necessarily cause total blindness. The 2014 meta-analysis projected 196 million people worldwide for 2020 (95% credible interval 140–261 million) and 288 million for 2040 (205–399 million). These are modelled projections, not measured current counts. The original 8 million with severe impairment in 2050 is a different, untraced endpoint and must not be confused with 8 million prevalent GA cases. 1 8
Use the Beckman clinical classification: medium drusen 63–<125 µm without AMD-related pigment abnormalities are early AMD; large drusen≥125 µm and/or relevant pigment abnormalities define intermediate AMD. Late AMD includes neovascular disease and geographic atrophy (GA). Small drusen alone are not automatically AMD. Stage each eye and distinguish drusen below the RPE from intraretinal hard exudates and subretinal drusenoid deposits. 1 2
02Separate clinical stage from the AREDS risk score
The original “Beekman” four-point description conflates two systems. Beckman is a clinical stage classification; the simplified AREDS risk score counts large drusen and pigment abnormalities across both eyes, giving levels 0–4. Neither the score nor a vein-width estimate around 125 µm replaces individual examination. Reticular pseudodrusen (RPD, subretinal drusenoid deposits) lie above RPE, unlike conventional sub-RPE drusen. 1 2 7
AREDS report 42 was a post-hoc analysis of 2719 AREDS and 1472 AREDS2 participants without late AMD in either eye at baseline. In AREDS, five-year late-AMD rates at levels 0–4 without RPD were 0.3%, 4.3%, 11.6%, 26.7% and 50.0%; with RPD they were 2.8%, 8.0%, 29.0%, 58.7% and 72.2%. At level 4 this was 80/160 versus 39/54. Late AMD included neovascular disease or any GA, including noncentral GA. Thus the original 50%/72% figures have a defined cohort, endpoint and denominator, not universal individual probabilities. 7
External AREDS2 estimates for levels 2–4 were 15.0%, 27.7%, 45.7% without RPD and 26.2%, 46.0%, 73.0% with RPD. RPD was graded using a deep-learning approach to colour photographs. This supports risk stratification, not an automatic extra-point rule or proof of causation. Trial-cohort selection, post-hoc analysis, image grading and calibration constrain transfer to other clinics; a larger predicted risk does not by itself prove better clinical decisions. 7
03Separate risk reduction from treatment of established disease
Age and family history inform risk; smoking is an important modifiable factor. Discuss smoking cessation, a balanced diet and general vascular health. The quoted 55% familial correlation is not an individual inheritance probability, and low lutein/zeaxanthin intake is not proof that deficiency alone causes AMD. The September 2026 German S1 risk/prevention guideline is identified; its exact full recommendations still require inspection before claiming detailed concordance. 1
Consider an AREDS2-type formulation in the appropriate intermediate/high-risk setting, not for primary prevention in every healthy eye or every early AMD. The original roughly 20% statement concerns an incompletely specified endpoint; NEI describes about 25% relative reduction in advanced AMD over 5 years with the original AREDS formulation. This is not a 25-percentage-point benefit or restoration of lost vision. Lutein/zeaxanthin replace beta-carotene in AREDS2-type formulations; current/former smokers should avoid beta-carotene-containing AREDS products. Check zinc/copper, vitamins C/E, interactions and the actual product with the clinician. 1 3
04Distinguish activity from atrophy and other fluid
Describe intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), blood and outer retinal integrity. IRF is often associated with worse visual outcomes than isolated SRF, but this is prognostic association, not a rule that every SRF pocket is harmless or that a dry scan ensures good function. Nonexudative degenerative cavities and tubulation can mimic active fluid. 1
GA is not defined universally by RPE loss above 175 µm, the export’s historical threshold. CAM cRORA requires the specified OCT combination of RPE attenuation/disruption and choroidal hypertransmission over≥250 µm with overlying photoreceptor degeneration and exclusion of RPE tear; iRORA denotes incomplete criteria. FAF supports extent/follow-up but low signal can also be blocked, and a bright border is not specific proof of metabolic failure. Use OCT and fundus/FAF together. 1 4
Type 1 macular neovascularisation (MNV/CNV) lies below RPE, type 2 above RPE in the subretinal space and type 3 is an intraretinal neovascular complex, historically RAP. These anatomical types do not map perfectly onto occult/classic FA leakage. Reticular pseudodrusen lie above RPE and mark increased progression risk, not a certain future outcome. OCT-A depicts flow without dye but does not show leakage; FA and selected ICGA answer complementary questions. 1
Fundus examination may show sharply demarcated depigmented areas with visible larger choroidal vessels. NIR can help delineate lesions, while hypo-FAF and peripheral hyper-FAF patterns need correlation with OCT rather than a fixed brightness rule. RPE/EZ loss, choroidal hypertransmission and inner-retinal subsidence (the original “waterfall”) describe changes; inner sagging or a reflective “bare Bruch membrane” alone does not establish iRORA or cRORA. Incomplete criteria must include the specified photoreceptor/RPE/transmission context, not only disappearance of one line. 1 4
05Assess atrophy progression without promising a timetable
The original GA estimates—at least 8 million symptomatic people, about 0.5% at 65–79 years, up to 11% in older cohorts, 16% legally blind and two thirds unable to drive—lack a traced population and definition here. Extrafoveal lesions may be asymptomatic, and legal blindness/driving criteria vary by jurisdiction. Explain central scotoma, reading limitations, independence and possible psychosocial consequences without assigning every patient this outcome. 1
Age, smoking, genetic background, fellow-eye disease, large or calcified/refractile drusen, RPD and choroidal features inform risk. The original ancestry, sun exposure, BMI and inactivity associations should not be treated as deterministic causes or a hierarchy for an individual. The quoted 1.6 mm²/year growth is not a linear forecast: size, multifocality, extrafoveal location and FAF patterns including diffuse-trickling influence observed growth and the measurement scale. 1
The original five precursor categories—large drusen, RPD, crystalline deposits, PED and vitelliform lesions—are retained as imaging contexts, not a required sequence or proof that RPD is always the most dangerous phenotype. The attributed German group and exact predictive model remain unverified. Diet/AREDS2 and PBM must not be presented as a guaranteed treatment for established extrafoveal GA; their populations and endpoints differ. 1
06Read atrophy treatment by endpoint and jurisdiction
Pegcetacoplan (Syfovre, C 3) and avacincaptad pegol (Izervay, C 5) entered U.S. GA care in 2023; this does not mean availability or authorisation everywhere. The original 20–25% slowing summarises selected anatomical outcomes across different trials, arms and time points, not guaranteed visual improvement or a universal effect. Discuss injection burden, conversion to neovascular disease and ocular inflammation alongside possible lesion-growth reduction. Full trial-specific effects and current local labels remain separate source tasks. 1
EMA’s re-examination confirmed a negative Syfovre opinion because the anatomical effect had not established a favourable clinical benefit–risk balance. Thus the export’s “available since 2023” cannot be used as a German treatment standard. Check the current jurisdiction-specific decision for each product; a past refusal is not evidence about a different medicine. 1 5
Photobiomodulation (PBM, Valeda) is not established routine AMD care. The July 2025 DOG/BVA/RG statement recommends use only in clinical trials because efficacy and safety remain uncertain. Its 9 sessions over 3–5 weeks describe a treatment course, not proof that mitochondrial activation improves vision. Regulatory clearance/CE marking and a recommendation for routine clinical benefit are different claims. 1 6
FDA granted the Valeda De Novo request on 4 November 2024 for a specified dry-AMD population: BCVA 20/32–20/70, at least 3 medium (>63–≤125 µm) or large (>125 µm) drusen or noncentral GA, and absence of neovascular disease/central GA. The decision describes roughly one ETDRS line after 2 years, not proof that slowing drusen growth was the primary benefit or that all extrafoveal GA should be treated. DOG’s dated July 2025 caution remains distinct from regulatory authorisation; full current local recommendations and IFU need checking. 9 6
The original 16–20% slowing for complement inhibitors combines unspecified trial arms/time points and does not mean visual recovery. EMA’s Syfovre refusal concerns clinical benefit–risk, not a demonstrated cost-based rejection of both drugs. Izervay had a separate application withdrawal in October 2024; full current regulatory and trial-specific review remains open. Do not infer one product’s status from the other. 1 11 12
07Treat active neovascular disease and monitor response
Anti-VEGF is the main treatment for active nAMD. Ranibizumab (Lucentis), aflibercept (Eylea, including 8 mg) and faricimab (Vabysmo, also targeting Ang-2) differ in study populations, schedules and labels; bevacizumab (Avastin) is used off-label in this setting. Treat-and-extend (T&E) adjusts a proactive interval to activity; PRN treats when indicated but still requires scheduled monitoring. Neither approach guarantees fewer visits or freedom from recurrence. 1
Brolucizumab is retained separately because intraocular inflammation/retinal vasculitis matters; longer intervals with 8 mg aflibercept or dual VEGF-A/Ang-2 faricimab are product- and response-specific, not guaranteed for every eye. A ranibizumab port delivery system (PDS) is a surgically implanted refillable reservoir; a roughly 6-month refill concept does not mean no procedures, no monitoring or no implant-related complications. Current local labels and availability require independent checking. 1
08Localise the neovascular complex and then judge activity
Type 1 lies below RPE and commonly has a PED/SRF pattern; a conspicuous PED and completely intact RPE are not obligatory in every scan. Type 2 occupies the subretinal space above RPE, often with classic FA leakage, but anatomy and leakage categories do not correspond perfectly. The original relative type-1 advantage and type-2 aggressiveness are tendencies, not guaranteed outcomes or reasons to defer treatment. 1
FLUID randomised 349 participants (174 intensive/175 relaxed); 279 (79.9%) completed 24 months. Both groups received ranibizumab 0.5 mg with monthly initiation then T&E. The relaxed protocol tolerated SRF except >200 µm at the foveal centre after IRF resolved. It did not compare untreated observation with injections. Full numerical efficacy/noninferiority results are not appraised here; this trial does not permit ignoring IRF, bleeding, symptoms or every SRF pocket. 10
PCV is an aneurysmal type-1-pattern differential: peaked PED, bubble sign and multilobulated M-shape can prompt selected ICGA. A domed PED is not a perfect exclusion, and pachychoroid is associated rather than mandatory. The original roughly 50% of Asian nAMD is population/definition dependent, not a universal ethnic rate. Haemorrhage risk and response guide anti-VEGF with selected PDT. 1
Type 3 (RAP) begins as an intraretinal complex associated with the deep retinal circulation; later downward extension and chorioretinal anastomosis (CRA) may occur. The original Yanuzzi/Gass priority debate remains an unchecked attribution, not a personal quotation. Retinal origin does not establish that choroidal involvement never occurs. Older age, RPD and choriocapillaris insufficiency are associations, not exclusion of conventional drusen or a single causal explanation. 1
Prominent IRF, intraretinal blood and hard exudates form the original RAP triad, but are not all mandatory or specific. SRF can coexist. The reported perifoveal 500–1500 µm and 75% temporal location are untraced cohort descriptions, not diagnostic cutoffs. Early anti-VEGF response can be good, while later atrophy/fibrosis limits function; neither an invariably poor outcome nor one fluid-location rule follows. 1
| Feature | GA | Type 1 | Type 2 | Type 3 / RAP |
|---|---|---|---|---|
| Mechanism | Progressive outer-retinal/RPE atrophy | Choroidal vessels below RPE | Vessels above RPE | Intraretinal complex with possible downward extension |
| Primary site | Outer retina, RPE, choriocapillaris | Sub-RPE | Subretinal | Deep retinal circulation |
| OCT | RPE/EZ loss, hypertransmission, subsidence | Often PED; intact RPE not guaranteed | Lesion above RPE, possible disruption | Prominent IRF, possible later CRA |
| Fluid tendency | No active exudation from atrophy alone; other disease may coexist | Often SRF | Often SRF | Often IRF; SRF may coexist |
| Drusen context | Large drusen / RPD | Often conventional drusen | Often conventional drusen | RPD association, not exclusion of drusen |
| Location | Often initially extrafoveal | May be central/subfoveal | May be central/subfoveal | Original perifoveal 500–1500 µm is not diagnostic cutoff |
| Course | Progressive loss, variable rate | Active exudation may respond well | May be aggressive | Often initially responsive |
| Long-term function | No established restoration of lost tissue | Relatively favourable tendency, no guarantee | Possible fibrosis and visual loss | Atrophy/fibrosis can limit recovery |
09AI measurements require validation before a clinical claim
Separate segmentation/quantification, prognosis and treatment selection. Algorithms may quantify EZ and RPE loss separately; a larger EZ-loss area may be investigated as a fast-progressor biomarker, not an established individual prognosis or indication to inject. Check acquisition, segmentation errors, external validation, calibration, missing images and patient-important outcomes rather than precision alone. 1
The original claim that this particular AI measure is FDA-recognised as a primary GA trial endpoint has not been traced to a regulator qualification or specific protocol here. An endpoint used in one trial is not universal regulatory qualification, and anatomical slowing is not synonymous with restored vision. Retain the claim as an explicit source question; do not endorse it from a device clearance or algorithm performance report. 1
10Agree monitoring, rehabilitation and emergency access
Teach monocular Amsler self-checking and prompt reporting of new distortion without promising that a normal grid excludes activity. Adapt visits to stage, fellow-eye risk and treatment, and offer low-vision support when needed. Discuss cataract and visual expectations briefly; detailed IOL/blue-light-filter decisions belong to the separate cataract/maculopathy review. Suspected post-injection endophthalmitis needs urgent specialist treatment, often intravitreal antibiotics with vitrectomy selected by severity; it is not a wait-for-next-visit problem. 1
What are the main learning points?
Stage and activity guide management. Supplements are for selected risk groups; anti-VEGF treats active neovascular disease, and slowing atrophy growth is not the same as improving vision.
When is assessment urgent?
New distortion, a central scotoma or rapid visual loss needs prompt assessment. Pain, marked redness or visual loss after an injection is an emergency.
References and access status
- 1Immutable original export; own AMD, atrophy and AI lecture; historical attribution/recording unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2Beckman clinical classification, Ferris et al.2013, PMID 23332590
Historical 183-age-related-macular-degeneration-2 appraisal reused; not new full-source access. Selected indexed classification abstract inspected 16 November 2026; direct page extraction empty, full article/supplement not read.
- 3NEI AREDS/AREDS2 frequently asked questions
Historical 183-age-related-macular-degeneration-2 appraisal reused; not new full-source access. Selected indication/formulation/relative-risk/smoking sections actually read 16 November 2026; sponsor explanation, not independent full trial appraisal.
- 4CAM report 3, Sadda et al.2018, PMID 29103793
Historical 183-age-related-macular-degeneration-2 appraisal reused; not new full-source access. Historical 016 appraisal reused with its dated scope; no fresh full-article inspection.
- 5EMA Syfovre refusal re-examination, EMA/432931/2024
Historical 183-age-related-macular-degeneration-2 appraisal reused; not new full-source access. Actual two-page extracted text read 16 November 2026; negative opinion and benefit-risk reasons, not complete assessment or other products/current local labels.
- 6DOG/BVA/RG Photobiomodulation statement,4 July 2025
Historical 183-age-related-macular-degeneration-2 appraisal reused; not new full-source access. All three extracted text pages including reference list read 16 November 2026; cited trials/FDA dossier and newer results not independently read.
- 7AREDS report 42, updated simplified severity scale, 2024
Primary structured abstract and selected methods/Table 5/external-validation/results/discussion passages read 17 November 2026. Post-hoc cohorts; no full supplement/figure appraisal.
- 8Wong et al., global AMD projection, 2014; PMID 25104651
Primary indexed projection results read 17 November 2026; direct PubMed incomplete, full meta-analysis not appraised.
- 9FDA Valeda De Novo decision DEN 230083, 4 November 2024
Actual extracted decision pp 1–4 indication/special controls read 17 November 2026; no full clinical decision review or IFU appraisal.
- 10FLUID randomised 24-month ranibizumab T&E trial; PMID 30502372
Primary indexed design/methods/participant and attrition passages read 17 November 2026; direct PubMed incomplete. Full numerical outcomes/noninferiority analysis and supplements not read.
- 11EMA Syfovre EPAR overview and refusal
Official overview/refusal explanation read 17 November 2026; final negative opinion 19 September/refusal 16 December 2024. Full assessment unread.
- 12EMA-hosted presentation: Izervay application withdrawal
Selected indexed EMA-hosted regulatory table read 17 November 2026: Izervay application withdrawn 24 October 2024. Not a full current regulatory assessment.
Original lecture link
For patients
AMD affects central vision. Monitoring each eye separately can help notice a change, but a normal home test cannot replace an examination.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
New distortion, a central scotoma or rapid visual loss needs prompt assessment. Pain, marked redness or visual loss after an injection is an emergency.
New distortion, a central scotoma or rapid visual loss needs prompt assessment. Pain, marked redness or visual loss after an injection is an emergency.